Corticosteroids in Treatment of Chronic Asthma SADIE D. WALSH,* M.B., M.R.C.P.ED.; I. W. B. GRANT,t M.B., F.R.C.P.ED. Brit. med. J7., 1966, 2, 796-802 Chronic or continuous bronchial asthma is a disabling and potentially dangerous disorder, for which the only effective treatment in the majority of cases is the administration of corticosteroids. There was at first some reluctance to use these agents on a long-term basis, mainly because of a discouraging report from the Medical Research Council (1956) , but in the past nine years many well-documented studies have testified to the value of this form of treatment (Phear, Ball, and Page, 1960; Bruce Pearson, Baylis, and Smellie, 1961; Livingstone and Davies, 1961; Rees and Williams, 1962) . There are indeed few respiratory physicians who do not now believe that it is indispensable to the management of severe chronic asthma.
In the Respiratory Diseases Unit of the Northern General Hospital, Edinburgh, corticosteroids have been used in the treatment of chronic asthma since 1953. Until 1958 we adopted the then orthodox policy of selecting patients for long-term treatment on purely clinical criteria. Patients with severe asthma which did not respond adequately to bronchodilator drugs were first given a seven-day course of corticosteroid. If the asthma was of the chronic or continuous type there was inevitably a recurrence of symptoms a few days or a few weeks after treatment was stopped. Another course of corticosteroid was then given, and the cycle of improvement and deterioration was usually repeated. After a time, often as a result of pressure from the patient or from the general practitioner, and seldom as a deliberate decision, a daily maintenance dose of corticosteroid was sanctioned by the consultant, and this form of long-term treatment, once started, could seldom be stopped, even for a day. This was clearly an unsatisfactory way to use a potentially dangerous drug, and in 1958 one of us (I. W. B. G.), working in collaboration with Dr. A. R. Somner, decided to experiment with methods of administering corticosteroids intermittently.
It had been observed that in most cases of chronic asthma the improvement produced by a short course of corticosteroid persisted for a few days after treatment was stopped, and there appeared to be fairly good grounds for assuming that, in some patients at least, symptoms could be controlled by the administration of corticosteroids for two or three consecutive days every week, or for a longer period every fortnight or every month. It seemed possible that if a regimen of this type could be used the various metabolic disturbances caused by the short courses of corticosteroid would subside or perhaps even be entirely reversed during the periods between treatment. Some support for this hypothesis has since been obtained from the work of Harter, Reddy, and Thorn (1963) , who showed that the metabolic effects of a single dose of prednisone given every 48 hours were substantially corrected during the second period of 24 hours after each dose was given. The results of our preliminary experience with intermittent corticosteroid therapy in chronic asthma were reported six years ago (Somner, Rogan, and Grant, 1960 This procedure could not always be followed in every detail. Some patients were in such severe respiratory distress when they were admitted to hospital that it would not have been safe to withhold treatment with corticosteroids in order to obtain " baseline " recordings of F.E.V. on inert tablets. The course we adopted in these cases (Fig. 2 e) was to give a large dose of prednisolone initially (up to 60 mg./day in a severe case), reduce it gradually to 20 mg./day as the symptoms subsided, and maintain this dose until the daily F.E.V. recordings reached a stable level. Inert tablets were then substituted and the assessment was continued according to the standard programme. If the F.E.V. fell after prednisolone was stopped this was usually taken to indicate that the asthma was responsive to corticosteroids, but a reversal of this trend following the reintroduction of prednisolone was deemed necessary for confirmation.
In some cases the serial F.E.V. recordings showed erratic variations which made it difficult or even impossible to assess the response to prednisolone. The F.E.V. might, for example, rise steadily for a few days and then fall sharply while prednisolone was still being given. This phenomenon appeared to be related in some instances to the development of respiratory infection, but in others no cause for it could be found. The policy we adopted in these cases was to repeat the assessment, if necessary, after the infection had been controlled by an antibiotic, and in most instances a more decisive result was obtained at the second attempt.
Another problem was that presented by those patients who did not respond to the standard dose (20 mg./day) of prednisolone but in whom there were indications from the history that the airways obstruction was at least partially reversible. The policy we adopted in these cases also was to repeat the assessment, but on the second occasion a higher initial dose (60-100 mg./day) of prednisolone was given. The dose was generally reduced to 20 mg./day for a few days before inert tablets were substituted, and the assessment was completed in the usual way. Such patients seldom proved to be suitable for intermittent treatment, and most of them required continuous treatment with a relatively high daily dose of prednisolone.
Subsequent Management of Patients Receiving Long-term Treatment
Results of Treatment in 245 Adults Distribution of Treatment Regimens (Table II Most of the patients who showed a +3 or a +2 response were able to return to regular employment, or in the case of married women to resume full household duties, although those with a +2 response usually had one or two periods of incapacity per year, each lasting for two to three weeks. The exceptions were those patients whose initial symptoms were not entirely due to reversible airways obstruction and who were left with a residual respiratory disability, presumably caused by emphysema, after the asthma had been effectively controlled. Patients in whom the response was classified at + 1 or 0 were regarded as treatment failures, although many of those in the + 1 response group claimed that the benefit they derived from the treatment enabled them to lead more active lives than hitherto. The reason for continuing treatment in those patients who showed no objective or subjective long-term response was the development of a curious phenomenon, which for lack of a better term will be described as "corticosteroid dependence." Attempts to withdraw treatment in these cases immediately provoked a complaint of increased dyspnoea. This was not associated with a reduction in F.E.V., and its cause is obscure. Some of these patients also experienced other symptoms, such as lassitude, mental depression, and arthralgia, when treatment was tentatively withdrawn or even when the dose was reduced. Corticosteroid dependence of this type apparently takes at least a month to develop, and can be avoided if treatment is not continued after the initial assessment has shown it to be of no value. In most of the cases in this series it had been induced before the patients were referred to hospital ; these patients had been given corticosteroids by their general practitioners for long periods before it was appreciated that the treatment was ineffective.
The response to treatment of the 245 adult patients in the various treatment groups is shown in Table V Incidence of Side-effects (Table VI) The majority of patients developed moonface, which was of marked degree in 38% of those on continuous treatment but in only 12% of those on intermittent treatment. In a few cases other manifestations of hypercorticism, such as facial plethora, acne, striae, hirsutism, purpura, and hypertension, were also noted. Peripheral oedema, often severe enough to warrant treatment with a diuretic, also occurred more frequently in patients receiving continuous treatment. The incidence of fractures occurring either spontaneously or as a result of minor trauma was much higher in patients on continuous treatment (15%) than in those on intermittent treatment (1%). Wedge fractures, often multiple, of vertebral bodies and cough fractures of the ribs accounted for all but one of the incidents. No attempt was made in these cases to withdraw corticosteroids or to reduce the dose, even in two patients who developed haematemesis. Instead, enteric-coated prednisolone tablets were substituted for the ordinary tablets, and the patients were treated with bed rest, diet, and antacids. With these measures the symptoms usually subsided rapidly, and there were no major complications apart from the two incidents of haemorrhage already mentioned. Two patients, however, ultimately required gastrectomy.
Less common side-effects included diabetes mellitus (3 cases), corticosteroid myopathy (1 case), muscle cramps (7 cases), and pulmonary tuberculosis (1 case). One patient developed rheumatoid arthritis and three patients had recurrence of eczema or psoriasis when attempts were being made to withdraw corticosteroids. The number of patients in whom these uncommon side-effects occurred was too small to provide any impression of their relative frequency in the two treatment groups.
So far as we are aware, none of the patients in the series ever showed an inadequate pituitary-adrenal response to stress, although this could not be altogether excluded in the case of those who died suddenly at home. All patients were issued with " steroid cards," which drew attention to this hazard and indicated how it could be avoided. In the series as a whole, those patients who sustained fractures were on average older (52.1 years) than those who did not (46.2 years), and males (8.3 %) were more prone to fractures than females (2.4%). This would seem to indicate that the liability to corticosteroid fractures is influenced by age and sex, the hazard being greatest in elderly subjects, particularly males.
Deaths (Table VII) Sixteen patients (6%) died during the period of observation, seven from status asthmaticus and nine from other causes. In those patients who died from status asthmaticus the main reason for the fatal outcome seems to have been a failure to
Results of Treatment in 28 Children
The ages of the 28 children (17 males and 11 females) treated ranged from 4 to 14 years. When the analysis was carried out 14 had been under treatment for one to three years, and the same number for longer periods. An analysis of the treatment regimens (Table VIII) showed that continuous (daily) treatment was more frequently required in children (40%) than in adults (26 %), and when an intermittent treatment regimen was used that in which corticosteroids were given on three consecutive days per week was less often effective in children than in adults. Provided a suitable regimen was used, however, the response to long-term treatment in children was no less satisfactory than that observed in adults (Table IX) . Over two- thirds obtained virtually complete symptomatic relief, and only one child out of 28 failed to derive significant benefit from the treatment. In many the improvement was dramatic, and in some of the younger children a fairly severe degree of chest deformity resolved completely after the asthma was controlled. The side-effects encountered in the children were marked hypercorticism in 15, and bleeding peptic ulcer, pulmonary tuberculosis, diabetes mellitus, and spontaneous fracture in one each. In general, the children required a proportionately higher dose of corticosteroid than the adults, and they were in consequence more liable to develop stigmata of hypercorticism. Only two serious side-effects were, however, encounterednamely, haematemesis from an acute gastric erosion in one case and a spontaneous fracture of a lumbar vertebra in another. Fortunately, complete recovery ensued in both cases. There were no deaths among the children in the series.
It was possible to reduce the initial maintenance dose, often considerably, in 50% of cases, and in 5 (18%) corticosteroid therapy was successfully withdrawn, a somewhat higher proportion than in the adult series (Table X) . Adults (245) 101 ( 410'') 12 (50I)
Children (28) 14 (50O) 5 (18°o) (Table XI) . Before treatment was started the mean height of 27 children in whom records were complete was 2 cm. less than that of comparable controls. After treatment was established 11 children increased in height at the normal rate, and six more rapidly than normal. In the remaining 10, however, there was clear evidence of a retarded rate of growth, which was pronouncd in two cases. As in all these children the asthma was well controlled, it is difficult to escape the conclusion that corticosteroids were responsible for the growth retardation. The weight of the children before and during treatment was also studied. The mean pretreatment weight was no less than 5.6 kg. below that of comparable controls, but it subsequently increased rapidly, and more than 50% of the children eventually became overweight.
Discussion
When this investigation was started in 1958 it was hoped to show that intermittent treatment with corticosteroids in suitably selected cases was just as effective as the conventional type of continuous (daily) treatment, but less likely to produce serious side-effects. With the method of assessment described in this paper it has been possible to identify those patients who are likely to respond satisfactorily to long-term corticosteroid therapy, and to select for most of them regimens of intermittent treatment which in practice have proved to be subjectively and objectively effective. Furthermore, the initial assessment has also indicated which patients are unlikely to respond to longterm treatment with corticosteroids, and has thus spared them unnecessary exposure to a potentially dangerous drug.
Because the policy which governed the selection of cases and the planning of treatment regimens differed fairly radically from that adopted in other studies, it has not been possible to make any precise comparison of the results in this series with those reported previously. The 33 unselected patients who formed series A in the group receiving continuous (daily) treatment were, however, managed along similar lines to the large series studied by Rees and Williams (1962) , and the results were virtually identical. There is no reason to believe that the indications for long-term treatment were any different in the remaining 212 patients than in the original series of 33. Nevertheless, the process of selecting patients for the various treatment regimens produced a sharp distinction between the results obtained with intermittent treatment on three days in seven or two days in four, which were better than those in the unselected cases of series A, and those obtained with intermittent treatment on alternate days or with elective continuous treatment (series B), which were worse than those in the unselected cases of series A.
The probable reason for these differences is that-patients in whom remissions of symptoms produced by prednisolone persist for two days or more after treatment is stopped have a type of asthma which is readily suppressed by corticosteroids. It is possible that the asthma in such cases could have been equally well controlled by a daily dose of prednisolone without exceeding the total weekly dose of 60 mg. used in our standard intermittent-treatment regimens. It could also be argued that the patients who received treatment on alternate days would have responded equally well, or possibly even better, to daily treatment, although they might have required a slightly higher dose than patients in the other two groups.
The whole concept of intermittent corticosteroid therapy could indeed be dismissed as a rather complicated way of separating patients into various grades of " corticosteroidresponsiveness" who merely required different daily doses of prednisolone to suppress their symptoms. It must be admitted that the higher incidence of side-effects observed in patients on continuous (daily) treatment may have been related in part to the higher annual dose of corticosteroid these patients received, and for that reason alone we cannot conclude that intermittent treatment is necessarily safer than continuous treatment. Nevertheless, we can reasonably claim that the policy we have pursued-in regard to the use of intermittent corticosteroid therapy has yielded results which are certainly not inferior in terms of either therapeutic efficacy or safety to those obtained by workers who have favoured the conventional practice of daily administration. There is still ample scope for experimentation in the logistics of corticosteroid administration in chronic asthma, and it is hoped that this paper will stimulate further efforts to devise the best possible method for utilizing these dangerous but often miraculously effective drugs.
Summary
An account is given of the results of treatment with prednisolone, and of the side-effects encountered, in 273 patients with chronic asthma (245 adults and 28 children) in whom treatment had been maintained for periods of 1 to 10 years.
In 180 (74%) of the 245 adult patients prednisolone was given intermittently (20 mg./day on three consecutive days per week, 17.5 mg./day on two consecutive days in every four, or 17.5 mg. on alternate days) ; the remainder received continuous (daily) treatment with an average dose of 10.1 mg./day. In 212 patients the response to prednisolone was tested by serial estimations of forced expiratory volume (1 second) before they were accepted for long-term treatment, and the length of remission after withdrawal of prednisolone was used to determine the appropriate regimen in each case. In the remaining 33 patients, who started corticosteroid therapy prior to 1958, no such preliminary assessment was undertaken, and they were all given continuous (daily) treatment.
The symptoms of asthma were almost completely relieved in two-thirds of those patients who were found suitable for treatment on three consecutive days per week or on two consecutive days in four, but in only one-third of those who required treatment on alternate days or every day. Those who received daily treatment without preliminary assessment showed a response midway between that observed in the first two categories. In the series as a whole 81 % of patients obtained a useful degree of symptomatic improvement, and in only 5 % was treatment totally ineffective. The maintenance dose of prednisolone was reduced, often considerably, in about 50% of cases, but it was possible to withdraw treatment completely in only 5%. Chronic Asthma-Walsh and Grant mittent treatment than with continuous (daily) treatment given in a comparable mean annual dose. The incidence of suspected and proved peptic ulceration was approximately the same in the two treatment groups. Sixteen patients (6%) died, seven from status asthmaticus and nine from other causes. The deaths from status asthmaticus were probably due to failure to increase the dose of corticosteroid when acute symptoms supervened. The death rate was no higher in patients on intermittent treatment regimens than in those given corticosteroids every day.
The results in 28 children were similar to those obtained in the 245 adults, but the children required a proportionately higher dose of corticosteroid, and were in consequence more liable to develop the stigmata of hypercorticism. More serious side-effects were uncommon, and no deaths were recorded. Intermittent treatment was effective less often in children than in adults, but complete withdrawal of corticosteroids was achieved more often in children (18%) than in adults (5%). Although growth had already been retarded in many children with severe chronic asthma before corticosteroids were given, it is possible that the administration of these agents was responsible for further retardation of growth in a few cases. This investigation has shown that in suitably selected cases regimens of intermittent treatment with prednisolone are as effective in controlling the symptoms of chronic asthma as continuous (daily) treatment. There are some indications that side-effects are less likely to be produced by intermittent than by continuous administration of prednisolone, but further studies will be required to confirm this tentative conclusion.
